Articles tagged with Cell Therapies
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
Researchers discover novel suppressive role of Ctdnep1 in osteoclast differentiation and bone resorption, suggesting potential therapeutic targets for treating excessive bone loss. The study reveals that Ctdnep1 functions as a brake on osteoclast cell differentiation.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
A study published in Radiology found that low-level light therapy increased resting-state functional connectivity in patients with moderate traumatic brain injuries. The treatment showed improved brain connectivity within the first two weeks, but its long-term effects are still unclear.
Researchers at the University of Houston have identified a subset of T cells called CD8-fit that show high motility and serial killing capabilities in patients with clinical responses. These cells were discovered using a patented approach called TIMING, which evaluates cell behavior and movement to identify potential cancer-killing cells.
Researchers at USask have discovered a new peptide that lowers lipid accumulation in human liver cells, offering new avenues for treating metabolic diseases. The finding is hopeful news as there's a lack of new therapies available for these diseases.
The study reveals that FLVCR1 and FLVCR2 transport choline and ethanolamine across cellular membranes, supporting cell growth and stability. This discovery contributes to understanding rare diseases and developing new therapies for patients suffering from severe neurological and muscular disorders.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A new study shows that gene therapy delivered by nanocarriers can repair damaged discs and reduce signs of back pain in mice. The treatment, which uses naturally derived nanocarriers to deliver genetic material for a protein key to tissue development, restored structural integrity and function to degenerated discs.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
University of Minnesota researchers found that immunotherapy improves CD8+ T-cell responses in older mice, reducing mortality from infections. The treatment, PD1 blockade, enhances the ability of T cells to kill harmful cells infected with a virus.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Dana-Farber researchers discovered a molecular complex called PI3Kgamma that supports the survival of certain leukemia cells. The team found that eganelisib, an existing medicine, can inhibit this complex and has shown promise in animal models and clinical trials.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
A massive study identifies new biomarkers for renal cell carcinoma subtypes, improving diagnosis and treatment. The researchers' integrative analysis of proteogenomic datasets reveals molecular features shared by clear cell and non-clear cell RCC tumors, as well as unique features to various subtypes.
Researchers at the University of Trento have identified a collection of molecular tools to rewrite DNA, including a compact Cas9 enzyme from the human microbiome. The discovery has potential for gene therapy applications and could speed up the development of therapies for genetic diseases.
The Ottawa Hospital is receiving a $59 million grant to boost Canada's capacity for life-saving biotherapeutics, including vaccines, gene therapies, and cell therapies. The funding will support the construction and operation of a world-class biomanufacturing facility at its new campus.
A new study found extensive alternative splicing of messenger RNA in untreated multiple sclerosis patients compared to healthy controls. Interferon-ß therapy corrected dysregulated alternative splicing, linking it to future clinical exacerbations.
Researchers found PLS occurs significantly more frequently in unequal AB0 settings, leading to haemolysis and anaemia in patients. Blood group A patients with O transplants are particularly at risk.
A new therapy has been identified that can penetrate the slime protecting drug-resistant bacteria, allowing it to be killed by the body's immune system or antibiotics. The antimicrobial peptide, derived from cow peptides, targets sugar connections in the slime structure, damaging its integrity and allowing entry.
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
Researchers at the University of Notre Dame found that adding a pre-ketone supplement to an immunotherapy treatment significantly reduced prostate cancer in laboratory settings. The combination therapy made tumors sensitive to immunotherapy, leading to 23% tumor cure rates and dramatic shrinking.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
Researchers developed a gene-based therapy that restored typical cellular function in organoids created from cells of people with Timothy syndrome. The treatment used antisense oligonucleotides to decrease the use of mutated exon 8A and increase reliance on non-affected exon 8, restoring normal calcium channel functioning.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Therapeutic phages can detect epithelial cells of the human respiratory tract, eliciting proinflammatory responses. Specific phage properties and airway microenvironment influence these responses.
Researchers at NJIT are developing a hydrogel therapy that prevents viruses like SARS-CoV-2 from attaching to and entering cells. The peptides in the gel form a 'molecular mask' that muffles the virus's action, providing a potential first line of defense against biological threats.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Scientists have identified a consistent signature of multiple sclerosis in the blood of patients years before they develop symptoms. The discovery, published in Nature Medicine, could lead to earlier diagnosis and treatment of the disease, affecting nearly 1 million people in the US.
Scientists at Salk Institute explore the clinical potential of cannabinol (CBN) in treating traumatic brain injury, Alzheimer's disease, and Parkinson's disease. They identify four CBN analogs with improved neuroprotective ability and drug-like efficacy.
A new study supports the use of neoadjuvant chemohormonal therapy for patients with locally advanced prostate cancer, showing improved biochemical progression-free survival and treatment-free survival rates. The treatment combination offers significant benefits in controlling PSA levels and potentially improving patient outcomes.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers at the University of Pittsburgh have discovered how to overcome resistance to conventional immunotherapies in metastatic uveal melanoma. They developed a clinical tool called Uveal Melanoma Immunogenic Score (UMIS) to predict patient response and improve treatment outcomes.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
New findings in The American Journal of Pathology indicate that periostin promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts. Periostin may be a promising therapeutic target for treating ESCC.
Researchers identified a gene mutation associated with impaired natural killer cell function, leading to increased susceptibility to viral infections in people with a rare genetic condition. Oleic acid supplementation shows promise as a potential therapy for these patients.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Two anti-inflammatory molecules, TGFβ1 and HpTGM, reduce the inflammatory response within the injured heart and scarring. Treatment with these proteins at the time of reperfusion reduces infarct size and mature scar size.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel antibody-drug conjugate (ADC) therapy that effectively kills T-cell cancers in mice with human T-cell tumors. The treatment targets TRBC1 protein expressed on the surface of cancer cells while preserving normal T cells.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
Researchers outline ferroptosis mechanisms and regulatory networks in lung cancer, highlighting potential therapeutic targets. The study suggests ferroptosis as a novel approach to overcome treatment resistance in lung cancer, providing hope for improving clinical outcomes.
A new analysis by researchers from Penn Medicine found that minority patients with lymphoma may be less likely to receive CAR T cell therapy due to clinical, provider, and socioeconomic barriers. The study assessed data from two cancer centers and found significant disparities in treatment access among minority populations.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A team of researchers at Weill Cornell Medicine has discovered a critical protein sensor called SEL1L that regulates collagen clearance from tissue. This finding provides new insights into the development of therapeutic strategies for diseases like lung fibrosis, which currently have no effective treatments.
A new study found that a viral infection can cause cognitive impairments by damaging the blood-brain barrier, leading to memory loss and learning difficulties. Researchers developed a gene therapy that stimulated the Wnt/beta-catenin pathway to prevent this damage and improve cognitive function in mice infected with SARS-CoV-2.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
NeXT Personal assay detects up to ~1,800 somatic variants specific to the patient's tumor with a detection threshold of 1.67 PPM and 99.9% specificity. The assay showed linearity over a range of 0.8 to 300,000 PPM.
Researchers developed a unique microfluidics-based diagnostic system that combines optical tweezers with stimulated Raman spectroscopy to enable fast and accurate diagnosis of leukemia. The device can identify cancer cells based on their metabolic activities and metabolites, providing tailored treatment options.